Research ArticleArticle
Mechanism for Covalent Binding of MLN3126, an Oral Chemokine C-C Motif Receptor 9 Antagonist, to Serum Albumins
Naohiro Narita, Akio Morohashi, Kimio Tohyama, Toshiyuki Takeuchi, Yoshihiko Tagawa, Takahiro Kondo and Satoru Asahi
Drug Metabolism and Disposition December 21, 2017, dmd.117.078782; DOI: https://doi.org/10.1124/dmd.117.078782
Naohiro Narita
Takeda Pharmaceutical Company Limited
Akio Morohashi
Takeda Pharmaceutical Company Limited
Kimio Tohyama
Takeda Pharmaceutical Company Limited
Toshiyuki Takeuchi
Takeda Pharmaceutical Company Limited
Yoshihiko Tagawa
Takeda Pharmaceutical Company Limited
Takahiro Kondo
Takeda Pharmaceutical Company Limited
Satoru Asahi
Takeda Pharmaceutical Company Limited
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
Mechanism for Covalent Binding of MLN3126, an Oral Chemokine C-C Motif Receptor 9 Antagonist, to Serum Albumins
Naohiro Narita, Akio Morohashi, Kimio Tohyama, Toshiyuki Takeuchi, Yoshihiko Tagawa, Takahiro Kondo and Satoru Asahi
Drug Metabolism and Disposition December 21, 2017, dmd.117.078782; DOI: https://doi.org/10.1124/dmd.117.078782
Research ArticleArticle
Mechanism for Covalent Binding of MLN3126, an Oral Chemokine C-C Motif Receptor 9 Antagonist, to Serum Albumins
Naohiro Narita, Akio Morohashi, Kimio Tohyama, Toshiyuki Takeuchi, Yoshihiko Tagawa, Takahiro Kondo and Satoru Asahi
Drug Metabolism and Disposition December 21, 2017, dmd.117.078782; DOI: https://doi.org/10.1124/dmd.117.078782
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement